Company News for Mar 16, 2026

Monday, Mar 16, 2026 6:54 am ET1min read
ADBE--
META--
NKTR--
ORKA--
Aime RobotAime Summary

- AdobeADBE-- shares fell 7.6% after CEO Shantanu Narayen announced his departure pending a successor.

- Meta's stock dropped 3.8% due to delayed release of its AI model "Avocado" until May 2026.

- NektarNKTR-- and Oruka TherapeuticsORKA-- shares rose 4.1% and 25% respectively after reporting narrower-than-expected Q4 2025 losses.

- Zacks highlighted potential "money-doubling" stock picks, surpassing previous success like Hims & Hers Health (+209%).

  • Adobe Inc.’s (ADBE) shares tumbled 7.6%, after the company announced that its longtime CEO Shantanu Narayen will step down once a successor is appointed.
  • Shares of Meta Platforms Inc. (META) slid 3.8% following news that the company has delayed the release of its new AI model "Avocado" to at least May.
  • Shares of Nektar Therapeutics (NKTR) surged 4.1% after reporting fourth-quarter 2025 adjusted loss of $1.78 per share, narrower than the Zacks Consensus Estimate of an adjusted loss of $2.76 per share.
  • Oruka Therapeutics Inc.’s (ORKA) shares soared 25% after posting fourth-quarter 2025 adjusted loss of $0.45 per share, narrower than the Zacks Consensus Estimate of an adjusted loss of $0.61 per share.


Zacks' Research Chief Picks Stock Most Likely to "At Least Double"

Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.

See Our Top Stock to Double (Plus 4 Runners Up) >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



Adobe Inc. (ADBE): Free Stock Analysis Report

Nektar Therapeutics (NKTR): Free Stock Analysis Report

Meta Platforms, Inc. (META): Free Stock Analysis Report

Oruka Therapeutics, Inc. (ORKA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet